- Home
- ENGN vs GNFT Comparison
ENGN vs GNFT Comparison
Compare ENGN & GNFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENGN
- GNFT
- Stock Information
- Founded
- ENGN 1999
- GNFT 1999
- Country
- ENGN Canada
- GNFT France
- Employees
- ENGN N/A
- GNFT N/A
- Industry
- ENGN
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- ENGN
- GNFT Health Care
- Exchange
- ENGN Nasdaq
- GNFT Nasdaq
- Market Cap
- ENGN 191.1M
- GNFT 186.3M
- IPO Year
- ENGN N/A
- GNFT 2019
- Fundamental
- Price
- ENGN $3.37
- GNFT $3.75
- Analyst Decision
- ENGN Buy
- GNFT Strong Buy
- Analyst Count
- ENGN 7
- GNFT 1
- Target Price
- ENGN $23.29
- GNFT $13.00
- AVG Volume (30 Days)
- ENGN 83.9K
- GNFT 3.8K
- Earning Date
- ENGN 09-09-2025
- GNFT 04-24-2025
- Dividend Yield
- ENGN N/A
- GNFT N/A
- EPS Growth
- ENGN N/A
- GNFT N/A
- EPS
- ENGN N/A
- GNFT 0.03
- Revenue
- ENGN N/A
- GNFT $73,187,701.00
- Revenue This Year
- ENGN N/A
- GNFT $15.98
- Revenue Next Year
- ENGN N/A
- GNFT N/A
- P/E Ratio
- ENGN N/A
- GNFT $120.71
- Revenue Growth
- ENGN N/A
- GNFT 105.01
- 52 Week Low
- ENGN $2.65
- GNFT $2.55
- 52 Week High
- ENGN $11.00
- GNFT $6.42
- Technical
- Relative Strength Index (RSI)
- ENGN 40.69
- GNFT 44.52
- Support Level
- ENGN $2.95
- GNFT $3.44
- Resistance Level
- ENGN $3.98
- GNFT $3.81
- Average True Range (ATR)
- ENGN 0.27
- GNFT 0.17
- MACD
- ENGN 0.02
- GNFT -0.00
- Stochastic Oscillator
- ENGN 34.29
- GNFT 56.65
About ENGN enGene Holdings Inc.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.
About GNFT GENFIT S.A.
Genfit SA is a biotechnology company focused on metabolic and inflammatory diseases, with a particular focus on the liver and gastroenterology. The company's research and development activity relies on its expertise in modulating gene expression through nuclear receptors. Genfit utilizes acquisitions, strategic alliances, and licensing agreements in order to fund the further development of its products. It has one segment the research and development of medicines and diagnostic solutions, the marketing of which depends on the success of the clinical development phase.